Quick Answer
Petros Pharmaceuticals, Inc. reported Net Income Loss of -$14.32 million for the year ending 2024.
- Petros Pharmaceuticals, Inc. showed a decrease of -75.4% in Net Income Loss from 2023 to 2024.
- This data is from Petros Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$6.08 million | Q2 2020: -$5.76 million | Q3 2020: -$3.30 million | Q1 2021: $3.01 million | Q2 2021: -$2.11 million | Q3 2021: -$1.70 million | Q1 2022: -$174.2 thousand | Q2 2022: -$1.81 million | Q3 2022: -$13.83 million | Q1 2023: -$1.39 million | Q2 2023: -$2.55 million | Q3 2023: -$4.55 million | Q1 2024: -$2.16 million | Q2 2024: -$662.0 thousand | Q3 2024: -$2.22 million | Q1 2025: -$2.26 million | Q2 2025: $5.43 million | Q3 2025: -$922.7 thousand.
- Over the full 5 years of available data (2020 to 2024), Petros Pharmaceuticals, Inc.'s Net Income Loss has grown by 30.4%.
- Historical annual values: Fiscal year 2024: -$14.32 million | Fiscal year 2023: -$8.16 million | Fiscal year 2022: -$20.04 million | Fiscal year 2021: -$8.99 million | Fiscal year 2020: -$20.59 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: